Login / Signup

Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2- advanced breast cancer.

Qi ZhaoMingxia JiangJiaxuan LiuMengqi ZhangMaiyue HeShihan ZhouJiani WangHongnan MoBo LanPeng YuanPin ZhangFei MaQiao LiBinghe Xu
Published in: Cancer biology & medicine (2024)
Cross-line CDK4/6i therapy is associated with significant clinical benefits and manageable safety profiles in patients with HR+/HER2- ABC, which underscores cross-line CDK4/6i therapy potential as an effective treatment strategy.
Keyphrases
  • cell cycle
  • stem cells
  • cell proliferation
  • climate change
  • cell therapy
  • human health
  • smoking cessation